AnaptysBio (NASDAQ:ANAB – Get Free Report) was downgraded by research analysts at HC Wainwright from a “buy” rating to a ...

Guggenheim lowered the firm’s price target on AnaptysBio (ANAB) to $36 from $90 and keeps a Buy rating on the shares following the announcement ...

Wells Fargo analyst Derek Archila lowered the firm’s price target on AnaptysBio (ANAB) to $40 from $56 and keeps an Overweight rating on the ...

Phase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.

Charles Schwab Investment Management Inc. raised its position in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 3.2% in the ...

Shares of AnaptysBio Inc. remained flat in premarket trading Thursday after plunging over 32% in the prior session, marking ...

Tom Yeung here with today’s Smart Money. In the 2000s, researchers at the University of California, Berkeley wondered, “What is the best predictor of a college student’s grades?” They studied dozens ...

Months Before C.E.O.’s Killing, the Suspect Went Silent. Where Was He? New details are emerging about Luigi Mangione’s growing impatience with “a capitalist society” and his search for ...

The Israeli prime minister said its forces would remain in Syrian territory until “a new force” filled the vacuum. Secretary of State Antony J. Blinken was in Jordan for talks on the aftermath ...

Columvi combo in DLBCL, while AnaptysBio's ANB032 fails in atopic dermatitis. Essential Pharma gets €1.2B financing deal.

Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., December 10, 2024. REUTERS/Brendan McDermid Wall Street pulled back on Thursday as investors evaluated key ...

Stay informed on Saudi Arabia’s rapid changes, developments, and ongoing efforts to reshape the Middle East and beyond.